-
Debate to focus on BMI and definitions of obesity
Body mass index (BMI) is one of the most controversial topics in the assessment of obesity today. Session Chair Robert Kushner, MD, previews a debate on whether this metric should be the primary tool in defining obesity.
-
Presenters to provide first look at data from REIMAGINE trials of cagrilintide/semaglutide for type 2 diabetes management
John B. Buse, MD, PhD, and other researchers will share study results and a broad understanding of amylin, from the hormone’s biology to potential translation to clinical care via phase 3 trials.
-
Symposium to highlight the latest chapters in the Standards of Care for Overweight and Obesity
The American Diabetes Association® (ADA) released the first chapters of this document in 2025. Kimberly Gudzune, MD, MPH, and other speakers will explain new standards on the screening and diagnosis of obesity, and on pharmacological treatments.
-
New clinical trial results to debut daily in New Orleans
Investigators will present high-impact results for type 1 diabetes, type 2 diabetes, and obesity in several clinical trial sessions. Glucagon-like peptide-1 (GLP-1)-based therapies—including dual and triple agonists, oral agents, and longer acting formulations—will be a recurring topic.